ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2492

The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

Rula Hajj-Ali1, Chao Zhang2, Renee Borchin3, Jenn Gordon4, David Cuthbertson3, Carol McAlear5, Christine Yeung5, David Badenoch6, Cristina Burroughs3 and Peter Merkel5, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3University of South Florida, Tampa, FL, 4Vasculitis Patient Powered Research Network (VPPRN), Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6Vasculitis Patient Powered Research Network (VPPRN), Los Angeles, CA

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Granulomatosis with Polyangiitis (GPA), neurology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Vasculitis – ANCA-Associated II

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Neurologic involvement (NI) is a common manifestation in patients with ANCA-associated vasculitis (AAV) and can lead to chronic pain and disability. This project assessed the impact of NI on health-related quality of life (HRQoL) in AAV.

Methods: Retrospective analysis of data provided from 2014-2022 by patients ≥18 years old with AAV [eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA)] enrolled in the Vasculitis Patient-Powered Research Network (VPPRN), an online registry. The VPPRN collects data regarding type of vasculitis, disease manifestations, information on how and when the diagnosis of vasculitis was established, and measures of HRQoL, including from multiple Patient-Reported Outcome Measurement Information System (PROMIS) domains. PROMIS measures generate T-scores with the mean T-score = 50 with a standard deviation of 10 in the reference population (U.S. general population). Data were analyzed according to NI involvement.

Results: Data from 1465 patients with AAV with available information on NI were included in this analysis; 901 of 1465 (61.5%) patients reported NI. Table 1 summarizes the demographic and clinical characteristics of patients with or without NI. Compared to patients without NI, those with NI were older at the time of diagnosis of AAV, were more likely to be diagnosed with GPA (vs. EGPA or MPA), be positive for ANCA, and more likely to have constitutional, musculoskeletal, skin, mucous membranes, ear/nose/throat, cardiovascular, pulmonary, and thrombotic manifestations of disease. The rate of renal involvement was the same among patients with or without NI. Patients with NI reported greater severity of vasculitis. There was no significant difference in the medications ever received among patients with NI vs patients with no NI.

Overall, patients with AAV reported reduced HRQoL in almost all domains compared to a reference population. Compared to patients without NI, patients with NI report higher scores for fatigue, depression, sleep disturbance, and pain interference, and lower scores for anxiety, social role, and physical function (Figure2).

Conclusion: NI, as reported directly by patients, is common in AAV, occurring in approximately two-thirds of patients. This rate is higher than has been reported through clinician-documented data, implying that physicians may be under-appreciating the extent of NI in AAV. NI is more common in GPA, compared to EGPA or MPA. Patients with NI have involvement of more organ systems than patients without NI. NI in patients with AAV has a negative impact on multiple domains of illness and health-related quality of life. These patient-reported data are informative for clinicians and patients with AAV and should raise the awareness of the impairment in patients with NI in AAV

Supporting image 1

Supporting image 2

PROMIS measures in patients with ANCA-associated vasculitis with (light blue) and without (dark blue) neurologic involvement: Compared to patients without neurologic involvement, patients with neurologic involvement had higher scores for fatigue, depression, sleep disturbance, and pain interference, and lower scores for anxiety, social role, and physical function


Disclosures: R. Hajj-Ali: Amgen, 2, GlaxoSmithKlein(GSK), 2, uptodate, 9; C. Zhang: None; R. Borchin: None; J. Gordon: Excision Biotherapeutics, 3; D. Cuthbertson: None; C. McAlear: None; C. Yeung: None; D. Badenoch: None; C. Burroughs: None; P. Merkel: AbbVie/Abbott, 5, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Cabaletta, 2, CSL Behring, 2, Eicos, 5, Electra, 5, Genentech, 5, GlaxoSmithKlein(GSK), 2, 5, HiBio, 2, InflaRx, 2, 5, Janssen, 2, Jubilant, 2, Kyverna, 2, 11, MiroBio, 2, Neutrolis, 5, Novartis, 2, NS Pharma, 2, Q32, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, Takeda, 2, 5, UpToDate, 9, Visterra, 2.

To cite this abstract in AMA style:

Hajj-Ali R, Zhang C, Borchin R, Gordon J, Cuthbertson D, McAlear C, Yeung C, Badenoch D, Burroughs C, Merkel P. The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-neurologic-involvement-in-anca-associated-vasculitis-on-self-reported-health-related-quality-of-life/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-neurologic-involvement-in-anca-associated-vasculitis-on-self-reported-health-related-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology